2025 is drawing to a close, and investors have plenty to look back on. Active ETF performance and proliferation was once again an important theme, and as the category matures, its standout performers have diversified.
When it comes to curing common ailments, the majority of doctors won't be prescribing things like LSD, mescaline, PCP, or psilocybin (mushrooms) anytime soon. But these are examples of a growing billion-dollar psychedelic drugs industry that's poised for even more growth.
SGDM, SLVP, SHLD, URA and PSIL top the charts in the first half of 2025, defying market turmoil and riding sector-specific surges.